Literature DB >> 21946305

Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.

Alison Huggins, Robert C Sergott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21946305     DOI： 10.1097/ICU.0b013e32834be03b

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN： 1040-8738            Impact factor:   3.761


× No keyword cloud information.
  3 in total

1.  Does fingolimod in multiple sclerosis patients cause macular edema?

Authors:  Kiran Turaka; Joseph Shepard Bryan
Journal:  J Neurol       Date:  2012-01-10       Impact factor: 4.849

2.  Pien Tze Huang Alleviates Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Mice by Regulating Th1 and Th17 Cells.

Authors:  Xuemei Qiu; Qingqing Guo; Xue Liu; Hui Luo; Danping Fan; Yongqi Deng; Hua Cui; Cheng Lu; Ge Zhang; Xiaojuan He; Aiping Lu
Journal:  Front Pharmacol       Date:  2018-10-31       Impact factor: 5.810

3.  Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.

Authors:  Rocco Totaro; Caterina Di Carmine; Gianfranco Costantino; Roberta Fantozzi; Paolo Bellantonio; Aurora Fuiani; Ciro Mundi; Stefano Ruggieri; Carmine Marini; Antonio Carolei
Journal:  Mult Scler Int       Date:  2015-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.